Premium
P4–177: Atrial fibrillation and mild cognitive impairment
Author(s) -
YanevaSirakova Teodora,
TarnovskaKadreva Rumiana,
Traykov Latchezar
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1568
Subject(s) - atrial fibrillation , medicine , concomitant , cardiology , montreal cognitive assessment , stroke (engine) , neuropsychology , cognitive impairment , cognition , psychiatry , disease , mechanical engineering , engineering
neuropsychological tests used were: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Hachinski ischemic index, Geriatric depression scale, 4Instrumental Activities of Daily Living Score. The mean MoCA and MMSE results were as follows: 23.8263.67 and 26.6262.20 on inclusion, 23.0263.85 and 26.7862.55 during follow-up. Results: We compared the group of carriers of ApoE4 with high risk for dementia with the non-carriers and found that there wasn’t any significant difference (at p1⁄40.05) in the mean MoCA and MMSE results between the two groups. On the other hand, there was a significant difference in the neuropsychological tests’ results between patients with controlled and poorly controlled hypertension (p1⁄40.048 for MoCA and p1⁄40.021 for MMSE). Patients with lower than 120/70 mmHg blood pressure were also with more advanced cognitive impairment (p1⁄40.022 for MoCA and p1⁄40.011forMMSE) than the others. Therewas also a significant (p<0.05) negative correlation between neuropsychological tests’ results and blood pressure variability. Antihypertensive treatment didn’t show any protective group effect. Conclusions: In patients with hypertension and other cardio-vascular risk factors, blood pressure control and variability, as well as diabetes, smoking, obesitas and dyslipidemia have the leading role for the clinical manifestation mild cognitive impairment. ApoE4 testing in the earliest phase of cognitive impairment in this population at risk doesn’t add any significant information for the risk profile of the patients.